seladelpar

Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
2 NASH drugmakers have wildly different Mondays
Biopharma Dive
Mon, 11/25/19 - 10:11 pm
Intercept Pharmaceuticals
CymaBay Therapeutics
FDA
NASH
seladelpar
obeticholic acid
CymaBay Therapeutics Stumbles in NASH Race, Shares Fall
Xconomy
Tue, 06/11/19 - 10:11 am
CymaBay
NASH
clinical trials
seladelpar
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
EP Vantage
Sat, 04/13/19 - 12:23 pm
Amgen
Enbrel
CymaBay
NASH
Erelzi
seladelpar
Genfit
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
CP Wire
Tue, 11/13/18 - 10:26 am
CymaBay
seladelpar
primary biliary cholangitis
NASH
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
Tue, 11/13/18 - 10:02 am
CymaBay
seladelpar
primary biliary cholangitis
NASH
CymaBay Initiates Ph III Study of Primary Biliary Cholangitis Drug
CP Wire
Tue, 10/30/18 - 11:22 am
CymaBay
primary biliary cholangitis
clinical trials
seladelpar
CymaBay Announces Positive Efficacy and Safety Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis
CP Wire
Wed, 04/11/18 - 11:57 pm
CymaBay
seladelpar
clinical trials